Objective. We examined the accuracy of the Papanicolaou (Pap) test among women with and women at high risk for human immunodeficiency virus (HIV) infection.
Cervical cancer is the second most common gynecologic malignancy among women in the United States and may be the most common AIDS-related cancer among women [1] . The number of US women with HIV infection continues to increase, because of new infections and because more-effective HIV therapies have led to significant decreases in mortality due to AIDS. Although these therapies prolong life, they do not prevent human papillomavirus (HPV) disease among HIV-infected women. Thus, clinicians face realistic concerns that the number of cervical cancer cases may increase, as well. Rates of abnormal results of cervical cytologic tests are 10-11-fold higher among HIVinfected women than among HIV-uninfected women, with abnormal findings revealed by 30%-60% of Papanicolaou (Pap) tests and evidence of dysplasia revealed by 15%-40% of Pap tests [1] . In addition, the rate of disease progression associated with abnormal Pap test findings appears to have increased [2] .
Cervical cytologic screening using the Pap test has been credited with the dramatic decrease in cervical cancer cases in the industrialized world during the past 50 years, because it facilitates detection and eradication of preinvasive lesions [3] . Although early studies suggested that results of Pap tests may be less accurate for persons with HIV infection [4, 5] , later reports showed comparable performance characteristics between HIV-infected women and HIV-uninfected women [6] [7] [8] [9] . However, questions remain about the accuracy of the Pap test, particularly for certain subsets of HIV-infected women, and the potential need for enhanced screening or evaluation based on laboratory markers of HIV infection and HPV disease.
This study examined the accuracy of the Pap test among women with and women at high risk for HIV infection by using colposcopy and biopsy as the gold standards. On the basis of our findings, we describe the effects of infection with high-risk HPV types, HIV-associated immunocompromise, HIV load, and treatment on the accuracy of the Pap test.
SUBJECTS AND METHODS
Women included in this study were participants in the HIV Epidemiology Research Study (HERS), a multicenter, prospective cohort study established by the Centers for Disease Control and Prevention to study the natural history of HIV in women. Women with or at risk for HIV infection were recruited from April 1993 through January 1995 from academic institutions participating in HERS in the Bronx, New York; Baltimore, Maryland; Detroit, Michigan; and Providence, Rhode Island. Eligibility criteria included documented HIV infection status within the previous 60 days or consent to HIV testing as part of screening, age of 16-55 years, and history of either injection drug use since 1985 or risky sexual behaviors (e.g., having ever had 15 sexual partners, traded sex for drugs or money, or engaged in sex with a male injection drug user or a man known or suspected to be HIV infected).
After enrollment, the visit protocol for all women in the HERS cohort included a standardized face-to-face interview, physical examination with a complete gynecologic examination, and specimen collection at 6-month intervals. Each interview included gynecologic and treatment history since the previous visit, drug use and sexual behaviors, updated selected demographic and psychosocial factors, and treatment history. For analysis, self-reported antiretroviral therapy was classified as any retroviral treatment (either HAART or regimens considered to be less effective [i.e., those usually comprised of 1 or 2 drugs]) versus no antiretroviral therapy. At each visit, HIVuninfected women were retested for HIV, and T cell counts and HIV load were determined for HIV-infected women. At each core visit, Pap testing and cervicovaginal lavage for HPV detection and typing were also performed. Additional information concerning HERS design and data collection methods has been described elsewhere [10] .
The current study included only women who were seen at the Baltimore HERS site, where colposcopy was routinely conducted for all women regardless of Pap test results. All women in this analysis had at least 1 study visit during which they underwent Pap testing and colposcopy. Women with hysterectomies were excluded from study enrollment. The analysis included data from the first 10 visits to the study sites by participants during 1993-1999.
Samples for Pap testing were collected with a cytobrush and wooden spatula from all women with a cervix and were submitted as conventional slide-based specimens. All Pap test results were evaluated using the 1991 revision to the Bethesda scoring system for cervical cytologic findings by a single commercial cytologic laboratory (Kyto Diagnostics [New York, NY]), where cytopathologists were blinded to participant HIV serostatus. Results were classified as normal, atypical cells of undetermined significance (ASCUS), or squamous intraepithelial lesions (SILs), unless otherwise specified. Most (85%) of the colposcopies occurred on the same day as the Pap test, and the remainder were performed within 3 months after a core visit. The study protocol specified that biopsy should be performed if colposcopy findings were abnormal and that endocervical curettage would be performed if colposcopy was deemed to be unsatisfactory (i.e., if the entire transformation zone was not visualized). Cervical biopsy findings were classified as normal, cervical intraepithelial neoplasia (CIN) I; CIN II; CIN III; or CIN, not otherwise specified (NOS). The clinicians performing the colposcopy were not consistently blinded to participant HIV infection status. Three clinicians performed all of the colposcopies and follow-up examinations. Women with suspected or documented high-grade intraepithelial lesions were referred for standard ablative or excisional treatment.
Cervicovaginal lavage specimens were collected by irrigating the cervix with 10 mL of normal saline solution followed by aspiration of the lavage fluid from the posterior vaginal fornix. Specimens were tested for HPV by PCR in a single laboratory, using consensus L1 primers with amplification of the gene encoding cellular b-globin as an internal control; the intensity of the PCR signal for HPV-positive specimens was graded on a scale of 1-4. The HPV type in the amplified product was identified by hybridization with a generic probe designed to recognize most HPV types and with HPV type-specific probes for HPV types 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45 , 51, 52, 53, 54, 55, 56, 58, 59, 66, 68, 73, 82, 83, and 84. Samples that were deemed to be positive for HPV by the generic probe mix but negative for HPV by all type-specific probes were considered to have untypeable HPV. An HPV risk category was assigned to each sample, according to the PCR-determined HPV type, as follows: types 16, 18, 31, and 45 were high risk; types 33, 35, 39, 51, 52, 56, 58, 59, 68, and 73 were intermediate risk; and types 6, 11, 53, 54, 55, and 66 were low risk. Samples from women with multiple HPV types were classified by the highest risk type assigned on the basis of PCR results. Specimens that were designated as PCR negative for HPV and PCR positive for the b-globin control were classified as having no HPV present. Selected demographic and behavioral characteristics were compared using x 2 analysis for categorical variables and Student's t test for continuous variables. Comparisons between variables that were not normally distributed were made using the Wilcoxon rank sum test. Both univariate and bivariate analyses for examining the correlation between Pap test results, colposcopy and biopsy findings, HPV infection status, and HIV infection status were performed using the 2-tailed Fisher exact test. Data from individual visits were analyzed using multivariate logistic models (generalized estimating equations) that corrected for multiple visits by individual women. Inferences were based on SEs estimated by robust methods using an m-dependent working correlation structure, which assumed that the correlation depended only on the interval between 2 visits. A P value of !.05 was considered to be statistically significant.
Informed consent was obtained from study participants. This study was approved by the institutional review board for the protection of human subjects at each participating HERS site and the Centers for Disease Control and Prevention.
RESULTS
This analysis included 284 women from the Baltimore HERS site, of whom 189 were HIV infected. Because the HERS cohort has been well described and compared with the general population of HIV-infected women in the United States, we compared the women in this single-site analysis with women in the overall HERS cohort. When controlled for HIV infection status, women in the Baltimore group did not differ from those in the other 3 groups in the number of live births (as assessed at enrollment) and the number of male sex partners during the 6 months before enrollment. However, women in this singlesite analysis were more likely to be African American, to be in the injection drug use risk cohort, to have an income of less than $500/month, to be a current smoker, to have used crack cocaine within the 6 months before enrollment, to have engaged in injection drug use in the 6 months before enrollment, and to be using hormonal contraceptives, compared with women from the other 3 sites. In addition, women from Baltimore were less likely to have completed high school, to have exchanged sex for drugs or money (as assessed at enrollment), and to have used condoms during sex within the 6 months before enrollment. A total of 63% of the women from Baltimore underwent colposcopy at visit 1, and 88%-95% underwent colposcopy at each subsequent visit.
Select demographic and behavioral characteristics at baseline are presented in table 1. As the table indicates, the HIV-infected women were more likely than HIV-uninfected women to have had a history of injection drug use, had lower monthly incomes, used condoms consistently, and had fewer sexual partners during the previous 6 months. In addition, the HIV-infected women were less likely to have used crack cocaine within the previous 6 months. The majority of the women in both groups were current smokers. The median CD4 cell count at baseline was 1039 cells/mL for HIV-uninfected women and 430 cells/mL for HIV-infected women; in accordance with the HERS design, HIV-infected women with an AIDS indicator condition were excluded, and only 36 infected women (19.1%) had CD4 cell counts at baseline of !200 cells/mL (data not shown). HPV was detected in 64.5% of HIV-infected women, compared with 28.8% of HIV-uninfected women ( ) (data not shown). P ! .01 Results of cervical cytologic and colposcopic analyses were available for 1200 women-visits among HIV-infected women and for 602 women-visits among HIV-uninfected women (table  2) . Abnormal cytologic findings were more common among HIV-infected women; most abnormal results of Pap tests were ASCUS or low-grade SIL. Detection of high-grade SIL by Pap testing were reported for 34 visits among HIV-infected women and for 6 visits among HIV-uninfected women. No differences were found with respect to colposcopic findings and HIV infection status for each category of Pap test results.
We next examined the correlation of histologic and cytologic findings of biopsies and Pap tests, respectively. For this analysis, visits were included only if a biopsy specimen was obtained or if no biopsy specimen was obtained but the colposcopic impression was normal. Among HIV-infected women examined during 478 visits, 143 biopsy specimens (29.9%) showed CIN. Of these, 8 (5.5%) were CIN II or CIN III. Among HIV-uninfected women examined during 141 visits, 18 (12.8%) biopsies revealed CIN, of which 2 (11.1%) were CIN II or CIN III. Among the women who underwent biopsy, the likelihood of finding CIN in women who had normal results of a Pap test was significantly greater for HIV-infected women (14.3%) than for HIV-uninfected women (1.2%) ( ). For HIV-P ! .01 infected women with normal results of a Pap test, the likelihood of detecting CIN during biopsy was significantly greater for NOTE. Data are proportion (%) of women and were not corrected for repeated measurements. Denominator includes subjects with normal or abnormal biopsy findings and subjects who had a normal colposcopic impression and did not undergo biopsy. ASCUS, atypical squamous cells of undetermined significance; SIL, squamous intraepithelial lesion. a CD4 cell count was not available for 1 patient. those with a CD4 cell count of !500 cells/mL. The diagnostic characteristics of Pap testing were compared between HIV-infected women and HIV-uninfected women. When detection of both ASCUS or SIL by Pap testing were considered to be abnormal, the sensitivity was 86.7% in the HIV-infected group versus 94.4% in the HIV-uninfected group ( ), the specificity was 65.8% versus 88.3% ( ), the P p .70 P ! .01 positive predictive value was 35.9% versus 28.3% ( ), P p .32 and the negative predictive value was 95.7% versus 99.7% ( ). When detection of ASCUS by Pap testing was ex-P ! .01 cluded, the sensitivity was 82.7% versus 90.0% ( ), the P p .88 specificity was 83.4% versus 97.9% ( ), the positive pre-P ! .01 dictive value was 51.7% versus 56.3% ( ), and the neg-P p .73 ative predictive value was 95.7% versus 99.7% ( ). P ! .01 We next examined predictors of discordant cytologic and histologic findings for women with normal results of Pap tests, because significant differences were found only among these women. Correlates were examined just for HIV-infected women, because only 1 HIV-uninfected woman with normal results of a Pap test had an abnormal biopsy finding. Individual models, which corrected for risk cohort and repeated measurements, were constructed for HPV risk categories, as well as for semiquantitative indicators of HPV load, CD4 cell count, HIV RNA levels, age, and current use of antiretroviral (mostly single or dual nucleoside) therapy. In this analysis, only the detection of HPV by PCR (OR, 3.1; 95% CI, 1.0-9.7) and a CD4 cell count of !500 cells/mL (OR, 6.1; 95% CI, 1.4-27.0) were significant predictors of abnormal biopsy findings (table  4) . In a multivariate model, a CD4 cell count of !500 cells/mL had an adjusted OR of 6.5 (95% CI, 1.5-29.2) and detection of HPV by PCR had an adjusted OR of 3.1 (95% CI, 1.0-9.8).
Of the 19 HIV-infected women with normal results of Pap tests and abnormal biopsy findings, 18 had abnormal Pap test findings (most often determined to be ASCUS) within 1 year before or after the discordant Pap test and biopsy findings (figure 1).
DISCUSSION
In this well-described cohort of women with and women at high risk for HIV infection, the correlation of cytologic findings with colposcopic and/or histologic findings was high. Most abnormal biopsy findings were found after abnormal Pap test findings: the accuracy of ASCUS and SIL Pap tests was high and did not differ by HIV infection status. We noted an increased risk of CIN among HIV-infected women with normal Pap test findings. HIV-infected women with a lower CD4 cell count and with HPV infection were at the highest risk of discordant findings.
Early reports raised concerns about the accuracy of cervical cytologic analysis for HIV-infected women, prompting some researchers to call for routine colposcopy for screening women with HIV infection [4, 11] , although other researchers found no apparent reduction in sensitivity [7, 8] . These early studies, however, were either small and uncontrolled or compared subjects with women whose HIV infection status was unconfirmed. Boardman et al. [12] compared discrepancies in cytologic-histologic findings for 41 HIV-infected women and 228 HIVuninfected women, all of whom were referred because of abnormal Pap test findings, and found no difference in the accuracy of the Pap test by HIV infection status. Our results were similar for abnormal Pap test findings.
Subsequent studies included larger samples and control groups with documented HIV-negative status. Wright et al. [6] reported a sensitivity and specificity of 81% and 87%, respectively, of Pap testing for detection of CIN in 398 HIV-infected women. The rate of false-negative results was 19%. Because 15 cases of CIN were detected in the HIV-uninfected group, the sensitivity, specificity, and rate of false-negative results could not be accurately assessed. The authors, however, pointed out that the rate of false-negative results seen for HIV-infected women was well within the range of 10%-40% usually reported for the general population [13] . Spinillo et al. [9] reported that the rate of false-negative results (i.e., normal Pap test findings with abnormal colposcopy or biopsy findings) for 241 HIVinfected women was 26.6%, compared with 16.2% for the control group of 404 HIV-uninfected women plus 587 women of unknown HIV infection status. This difference was not statistically significant. The negative predictive value of cytology was significantly lower among HIV-seropositive women than among women in the control group. Recently, Goodman et al. [14] compared 82 HIV-uninfected women with 102 HIV-infected women and found that abnormal histologic findings were associated with normal cytologic findings for 14.3% of the HIVuninfected women and for 10.5% of the HIV-infected women. Conversely, in this study, HIV-infected women with normal results of Pap tests were more likely to have CIN than were HIV-uninfected women with normal results of Pap tests.
Several weaknesses in our analysis must be acknowledged. Because colposcopists were not always blinded to HIV infection status, there may have been a lower threshold to perform biopsies for women with HIV infection or abnormal results of Pap tests, potentially biasing findings. In addition, the study was limited by the following factors: relative immunocompetence of the HIV-infected women, reflecting entry criteria for the study that enrolled women with less advanced HIV disease; a small number of women with high-grade lesions; a paucity of HIV-infected women receiving what is now considered to be adequate antiretroviral therapy; and a relatively small sample size with limited statistical power. Furthermore, although colposcopic and histologic analyses were used as the gold standard in this study, the inter-rater agreement for histologic findings is no greater than that for cytologic findings in general, and colposcopic and histologic analyses may be limited by inability to visualize the entire transformation zone or by sampling difficulties. Calculation of a weighted k statistic to examine agreement between Pap test results and colposcopic impression for all women analyzed was .32, reflecting marginal concordance.
The current study had several strengths. The study population was a well-described cohort of women with and women at risk for HIV infection who were eligible for enrollment by fulfilling specific criteria. This cohort ensured greater comparability between HIV-infected subjects and women in the control group than that observed in previously reported studies. This study also examined the accuracy of the Pap test among subgroups of HIV-infected women while controlling for potential confounders. Colposcopy was performed at each visit, regardless of Pap test results, and use of repeated observation analyses increased analytical power. In 85% of the cases, the colposcopist was blinded to the Pap test results. This study was able to control for a variety of factors not examined in previous studies, including HIV load and quantitative measures of the HPV load in the genital tract.
In summary, we found that Pap tests were more likely to have false-negative results for HIV-infected women who had CD4 cell counts of !500 cells/mL; however, all abnormalities in this population were low-grade lesions, and of the 19 HIVinfected women with normal results of Pap tests and CIN, 95% would have had cytologic abnormalities detected within 1 year after the discordant results by using current guidelines for Pap testing. Our data fail to support the need for routine colposcopy for all HIV-infected women or for women with more-advanced immunosuppression. The question of Pap test accuracy, particularly for women with normal cytologic findings, should be evaluated further in a prospective fashion, with larger numbers of subjects and with newer cytologic screening technologies and/or adjunctive HPV testing strategies. 
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